Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial.

By T. Griffiths, ML Burr, I. Campbell, V. Lewis-Jenkins, J. Mullins, K. Shiels, PJ Turner-Lawlor, N. Payne, R. Newcombe, AA Lonescu and 2 more. The Lancet, 2000

1,002 citations recorded by the source corpus.

Subfields: Neurology, Pulmonary and Respiratory Medicine, Sociology and Political Science

View Paper: https://www.semanticscholar.org/paper/4059328b782e144d96442633654bd88c0c07dc11

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. D. Parums
2. Bartolome Celli
3. Alvar Agusti
4. B. K. Pedersen
5. P. Calverley
6. W. Bailey
7. L. Gerald

In Sociology and Political Science

1. D. Parums
2. W. Bailey
3. L. Gerald

Citations in the corpus

• Health status measurement in chronic obstructive pulmonary disease (2001, background): “although the generic SF-36 has shown responsiveness in pulmonary rehabilitation.”
• Editorial: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines for COPD, Including COVID-19, Climate Change, and Air Pollution (2023, positive): “Исследования показывают, что данные измене! ния могут сохраняться даже после одного курса реаби! литации [341, 384, 385].”
• Systemic effects of chronic obstructive pulmonary disease (2003, background): “Currently, this is based mostly upon rehabilitation programmes, nutritional support and, perhaps, oxygen therapy [9–11, 13, 43, 76, 139].”
• Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. (2003, neutral): “33 FEV1/FVC, % 45 46 Dyspnea, ATS-DLD-78, grade 5 47 (49) 44 (46) 6-min walking distance, m 280 ± 90 282 ± 91 Respiratory drugs at time of enrollment Short-acting 2 agonist 75 (80) 80 (84) Long-acting 2 agonist 15 (16) 13 (14) Anticholinergic 58 (62) 63 (66) Combined B2 and anticholinergic 23 (24) 2”
• Interpreting thresholds for a clinically significant change in health status in asthma and COPD (2002, background): “Health status changes of this size have been described in pulmonary rehabilitation [19, 20 ].”
• American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. (2006, background): “An 18-session, 6-week outpatient pulmonary rehabilitation program decreased inpatient hospital days and decreased the number of home visits when compared with standard medical management (307).”
• Exercise as medicine – evidence for prescribing exercise as therapy in 26 different chronic diseases (2015, background): “Studies show that rehabilitation programs lead to fewer hospitalizations and thus save resources (Griffiths et al., 2000; Griffiths et al., 2001).”
• Evidence for prescribing exercise as therapy in chronic disease (2006, background): “Newer trials are also available showing that rehabilitation programs result in fewer admissions and thereby save on resources (Griffiths et al., 2000, 2001).”
• Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease (2012, background): “The beneficial effects of a comprehensive pulmonary rehabilitation program are not sustained beyond 12 months [32, 42, 144, 145].”